Right now, there are thousands of people who need a heart transplant, yet there are not nearly enough organs available to meet that need. Additionally, those who do receive a donor heart run the risk of rejection and must on lifelong immunosuppressants, which consequently makes them more susceptible to infection. As Dr. Jeffrey Morgan, M.D., says, with the methods we have in place today, heart transplant recipients are essentially trading one disease for another.
Dr. Morgan is the Chief Medical Officer at BIOLIFE4D, a biotech company that is developing a bioartificial heart, which would increase availability of hearts for transplantation and eliminate the risk of rejection, as the heart would be generated from the patient’s own cells.
Press play to hear more. Be sure to visit the BIOLIFE4D website at https://biolife4d.com.